Agios Pharmaceuticals, Inc.
AGIO
$29.20
-$1.03-3.41%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 19.97M | 12.88M | 12.46M | 8.73M | 10.73M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 19.97M | 12.88M | 12.46M | 8.73M | 10.73M |
| Cost of Revenue | 89.94M | 88.48M | 93.64M | 73.83M | 84.07M |
| Gross Profit | -69.97M | -75.60M | -81.19M | -65.10M | -73.34M |
| SG&A Expenses | 51.61M | 41.27M | 45.87M | 41.53M | 51.70M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 141.55M | 129.75M | 139.51M | 115.36M | 135.77M |
| Operating Income | -121.58M | -116.87M | -127.06M | -106.63M | -125.04M |
| Income Before Tax | -109.06M | -103.43M | -112.02M | -89.29M | -105.40M |
| Income Tax Expenses | -1.02M | -- | -- | -- | -8.88M |
| Earnings from Continuing Operations | -108.04M | -103.43M | -112.02M | -89.29M | -96.52M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -108.04M | -103.43M | -112.02M | -89.29M | -96.52M |
| EBIT | -121.58M | -116.87M | -127.06M | -106.63M | -125.04M |
| EBITDA | -120.31M | -115.50M | -125.80M | -105.35M | -123.67M |
| EPS Basic | -1.85 | -1.78 | -1.93 | -1.55 | -1.69 |
| Normalized Basic EPS | -1.17 | -1.11 | -1.21 | -0.97 | -1.15 |
| EPS Diluted | -1.85 | -1.78 | -1.93 | -1.55 | -1.69 |
| Normalized Diluted EPS | -1.17 | -1.11 | -1.21 | -0.97 | -1.15 |
| Average Basic Shares Outstanding | 58.35M | 58.14M | 57.93M | 57.46M | 57.10M |
| Average Diluted Shares Outstanding | 58.35M | 58.14M | 57.93M | 57.46M | 57.10M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |